Somewhat Positive Press Coverage Somewhat Unlikely to Affect Wave Life Sciences (WVE) Stock Price
Media headlines about Wave Life Sciences (NASDAQ:WVE) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Wave Life Sciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.4173978983733 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of analysts recently weighed in on the stock. Mizuho set a $34.00 price objective on shares of Wave Life Sciences and gave the stock a “buy” rating in a research note on Friday, August 18th. Jefferies Group reaffirmed a “buy” rating and issued a $40.00 price objective (down from $42.00) on shares of Wave Life Sciences in a research note on Thursday, August 10th. BidaskClub raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Zacks Investment Research raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $53.00 price objective (up from $42.00) on shares of Wave Life Sciences in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Wave Life Sciences has an average rating of “Buy” and an average target price of $41.60.
Wave Life Sciences (NASDAQ WVE) opened at $36.55 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.50 and a current ratio of 11.50. Wave Life Sciences has a 1 year low of $15.15 and a 1 year high of $39.70.
Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.94) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.97) by $0.03. Wave Life Sciences had a negative net margin of 3,866.12% and a negative return on equity of 59.10%. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.77 million. equities analysts expect that Wave Life Sciences will post -3.76 EPS for the current fiscal year.
In other news, insider Chandra Vargeese sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, Llc acquired 423,398 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were purchased at an average cost of $23.34 per share, for a total transaction of $9,882,109.32. The disclosure for this purchase can be found here. 53.00% of the stock is owned by company insiders.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.